- Home
- SNY vs ITRM Comparison
SNY vs ITRM Comparison
Compare SNY & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNY | ITRM |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | France | Ireland |
| Employees | 74846 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.6B | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SNY | ITRM |
|---|---|---|
| Price | $44.96 | $0.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $58.00 | $9.00 |
| AVG Volume (30 Days) | 2.6M | ★ 30.9M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.49 | N/A |
| Revenue Next Year | $6.10 | $947.65 |
| P/E Ratio | $6.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.33 | $0.03 |
| 52 Week High | $53.02 | $1.16 |
Technical Indicators
Market Signals| Indicator | SNY | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 52.91 | 26.10 |
| Support Level | $43.32 | N/A |
| Resistance Level | $48.76 | $0.39 |
| Average True Range (ATR) | 0.57 | 0.02 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 95.89 | 3.34 |
Price Performance
Historical ComparisonAbout SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.